Read more

September 30, 2022
1 min read
Save

Top in rheumatology: Medical gaslighting; Inflation Reduction Act

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The power imbalance between patients and providers can lead to medical gaslighting, which rheumatology patients have been experiencing for decades, according to experts.

Rheumatological diseases are often a constellation of symptoms and abnormalities, resulting in under- or over-diagnoses, or no diagnoses. Many patients feel dismissed by their physicians, especially underrepresented populations. A review about the challenges caused by medical gaslighting was the top story in rheumatology last week.

StressPatient1_172195110
Source: Adobe Stock

Another top story covered the Inflation Reduction Act of 2022. The act was signed into law by President Joe Biden on Aug. 16 and contains numerous provisions that could benefit those with rheumatic and autoimmune diseases, experts said.

Read these and more top stories in rheumatology below:

‘Paradigms of distrust’: Medical gaslighting leaves patients dismissed and disrespected

The word “gaslighting” has taken on a life of its own in recent years, being used in the context of interpersonal relationships, political discourse and online chatter alike. Read more.

‘Unprecedented’: How the Inflation Reduction Act of 2022 could impact rheumatology

It remains up in the air whether the Inflation Reduction Act of 2022 will live up to its name in terms of economic impact. Read more.

Pain Awareness Month: Patients with Sjögren’s syndrome rate their pain at 5 out of 10

One of the defining characteristics for many rheumatic diseases, including Sjögren’s syndrome, is the presence of pain and fatigue. Read more.

Biosimilar-to-biosimilar switching safe, effective in rheumatology

Although biosimilar-to-biosimilar switching is not covered by health regulations or guidance, a systematic literature review suggests the practice is safe and effective, according to data published in BioDrugs. Read more.

Litifilimab superior to placebo in patients with cutaneous lupus erythematosus

Litifilimab (BIIB059, Biogen) is superior to placebo in improving CLASI-A scores among patients with cutaneous lupus erythematosus over 16 weeks, according to data published in The New England Journal of Medicine. Read more.